Table 3. Incidence and multiplicity of liver tumorsa.
| Tumor type - Incidenceb | Multiplicityc | |||||||
| Genotype | Group | # Mice in which livers were examined | # Mice with tumors | Hepatocellularadenoma | Hepatocellular carcinoma | Adenoma and carcinoma | Total hepatocellular adenomas | Total hepatocellular carcinomas |
| TGFα/TrsptG37 | 1B | 14 | 12 | 8/14 (57%) | 7/14 (50%) | 3/14 (21%) | 10 | 16 |
| 1C | 26 | 17 | 11/26 (42%) | 12/26 (46%) | 6/26 (23%) | 16 | 23 | |
| 1D | 19 | 14 | 9/19 (47%) | 10/19 (53%) | 5/19 (26%) | 12 | 18 | |
| TrsptG37/+ | 2B | 13 | 4 | 4/13 (31%) | 0/13 (0%) | 0/13 (0%) | 4 | 0 |
| 2C | 19 | 3 | 3/19 (16%) | 0/19 (0%) | 0/19 (0%) | 3 | 0 | |
| 2D | 18 | 7 | 6/18 (33%) | 1/18 (6%) | 0/18 (0%) | 10 | 1 | |
| TGFα/+ | 3A | 21 | 12 | 7/21 (33%) | 8/21 (38%) | 3/21 (14%) | 7 | 10 |
| 3B | 21 | 17 | 12/21 (57%) | 11/21 (52%) | 6/21 (29%) | 15 | 14 | |
| 3C | 20 | 15 | 12/20 (60%) | 8/20 (40%) | 5/20 (25%) | 16 | 11 | |
| 3D | 19 | 14 | 9/19 (47%) | 12/19 (63%) | 7/19 (37%) | 14 | 16 | |
| 3E | 18 | 12 | 8/18 (44%) | 10/18 (56%) | 6/18 (33%) | 10 | 13 | |
| +/+ | 4A | 10 | 0 | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) | 0 | 0 |
| 4B | 6 | 2 | 2/6 (33%) | 1/6 (17%) | 1/6 (17%) | 3 | 2 | |
| 4C | 8 | 1 | 1/8 (13%) | 0/8 (0%) | 0/8 (0%) | 2 | 0 | |
| 4D | 9 | 1 | 1/9 (11%) | 1/9 (11%) | 1/9 (11%) | 1 | 1 | |
| 4E | 8 | 1 | 0/8 (0%) | 1/8 (13%) | 0/8 (0%) | 0 | 1 | |
a
Tumor incidence and multiplicity of groups were compared using Fisher’s Exact test (see text).
b
Fraction of mice with each cancer type. Percent of mice with the tumor type shown in parentheses. In addition to adenomas and carcinomas, one mouse in Group 1B had two hepatoblastoma and one mouse in Group 3E had one hemangiosarcoma.
c
Total number of hepatocellular adenomas or carcinomas in all mice.